

Q&A summary for the 163rd Annual General Meeting of Shareholders

Pre-meeting Question from shareholders 1

Question	Cough has been reported as a side effect of soralutinib, an inhaled PDGFR inhibitor currently under development as a treatment for PAH. Has a similar side effect been observed with NS-863, which is being developed as an oral PDGFR inhibitor? Are there any other reported side effects?
Answer	No cough was observed in the Phase 1 trial of NS-863 in healthy adults. Furthermore, no serious adverse events were reported in the Phase 1 trial, and good tolerability was confirmed.

Pre-meeting Question from shareholders 2

Question	The oral PDGFR inhibitor NS-863 is currently being developed as a treatment for PAH, but is there a possibility it could also be developed as an anticancer agent?
Answer	We are currently focusing our development efforts on PH, and we plan to evaluate other indications based on clinical trial data and other information.

Note: No questions were asked at the shareholders' meeting.